Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Locally Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Locally Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etakafusp alfa (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Head and neck cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Asher Biotherapeutics

    • Most Recent Events

    • 09 May 2024 Planned End Date changed from 1 Oct 2025 to 1 May 2027.
    • 09 May 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Aug 2026.
    • 16 Apr 2024 According to an Asher media release, company announced the closing of a Series C financing, which raised $55 million and plans to use the proceeds from this financing to fund further development of AB248 through Phase 1b monotherapy expansion data, as well as initial safety and efficacy results from the ongoing combination with pembrolizumab.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top